International Stem Cell announced in July 2016 that it had dosed the first patient in the Phase I dose escalation study examining its neural stem cell product ISC-hpNSC for the treatment of moderate to severe Parkinson’s disease. The study will enrol 12 patients at three dosing regimens with a primary endpoint of safety, but will provide preliminary efficacy data measured at six and 12 months following the treatment.
02 Aug 2016
First patient dosed in Phase I trial
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
First patient dosed in Phase I trial
- Published:
02 Aug 2016 -
Author:
Maxim Jacobs -
Pages:
5
International Stem Cell announced in July 2016 that it had dosed the first patient in the Phase I dose escalation study examining its neural stem cell product ISC-hpNSC for the treatment of moderate to severe Parkinson’s disease. The study will enrol 12 patients at three dosing regimens with a primary endpoint of safety, but will provide preliminary efficacy data measured at six and 12 months following the treatment.